Alzheimer’s Antibody Drugs in 2026: What Medicare Covers, Who Qualifies, and What Patients Should Know

The short version: Anti-amyloid antibody drugs like lecanemab (Leqembi) are available in the United States for people with early Alzheimer’s disease—not advanced dementia. Medicare generally covers them under specific conditions. Treatment requires confirmed amyloid in the brain, regular infusions, and scheduled MRI scans to monitor for brain swelling or bleeding. These drugs do not cure Alzheimer’s, but in clinical trials they modestly slowed decline over about 18 months.

Here’s what families need to know in 2026.

1. What These Drugs Are—and Who They’re For

Lecanemab (brand name Leqembi) is an anti-amyloid monoclonal antibody. It is designed to attach to and help clear amyloid-beta, a protein that builds up in the brains of people with Alzheimer’s disease.

According to the U.S. Food and Drug Administration (FDA), lecanemab is approved for people with:

Mild cognitive impairment (MCI) due to Alzheimer’s disease, or
Mild dementia due to Alzheimer’s disease,

and confirmed evidence of amyloid pathology in the brain.

It is not approved for people with moderate or advanced dementia. That distinction matters. Many people with memory problems do not qualify, either because their disease is too advanced or because their dementia has a different cause (such as vascular dementia or Lewy body dementia).

The National Institute on Aging notes that Alzheimer’s disease progresses gradually from mild to more severe stages. These antibody drugs are aimed at the earliest symptomatic phase, when daily independence is still mostly preserved.

2. What the FDA Approval Actually Means

In 2023, the FDA granted traditional approval to lecanemab based on results from a large randomized clinical trial known as CLARITY-AD. Traditional approval means the agency determined the drug demonstrated clinical benefit, not just changes in a laboratory marker.

In that trial of nearly 1,800 participants with early Alzheimer’s disease, people receiving lecanemab experienced about a 27% slower rate of decline on a standard cognitive and functional scale over 18 months compared with placebo.

Two important points:

The drug slowed decline; it did not stop or reverse the disease.
The main evidence covers about 18 months of treatment. Longer-term outcomes are still being studied.

This is why experts describe the benefit as modest but meaningful for some families. Slowing decline may translate into several additional months of higher independence, but it does not restore lost memory.

3. How Medicare Coverage Works in 2026

Access in the United States depends heavily on Medicare policy.

Under the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination for anti-amyloid monoclonal antibodies:

Medicare covers FDA-approved anti-amyloid antibodies when used according to the FDA label.
Patients must have a diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Amyloid pathology must be confirmed (usually by PET scan or cerebrospinal fluid testing).
Treatment must occur in settings that participate in required data collection (a registry).

That registry participation is not optional for coverage. CMS requires real-world data collection to monitor outcomes and safety.

For patients with traditional Medicare, these drugs are typically covered under Part B (medical insurance), because they are given by infusion. That means:

Patients are generally responsible for 20% coinsurance after meeting the Part B deductible.
Supplemental coverage (Medigap, employer retiree coverage, or Medicaid) may reduce out-of-pocket costs.
Costs can vary depending on individual coverage and infusion center charges.

Families should ask for a clear estimate of infusion, imaging, and visit costs before starting therapy.

4. Safety Monitoring: Understanding ARIA and MRI Requirements

The most important safety issue with these drugs is something called amyloid-related imaging abnormalities, or ARIA.

As explained by the FDA and detailed in a review published in JAMA, ARIA refers to:

ARIA-E: brain swelling (edema)
ARIA-H: small areas of bleeding or microbleeds in the brain

In clinical trials, ARIA occurred in a minority of patients. Many cases were detected only on MRI and caused no symptoms. When symptoms did occur, they could include:

Headache
Confusion
Dizziness
Visual changes
Nausea

Serious complications were uncommon but have been reported.

Because of this risk, patients must have:

A baseline MRI before starting treatment
Periodic MRIs during early treatment to monitor for ARIA

People who carry the APOE ε4 genetic variant have a higher risk of ARIA. Many clinicians discuss optional genetic testing before treatment to better understand that risk. Patients on certain blood thinners or with multiple prior brain bleeds may face additional risk, and some may not be candidates.

5. What the Clinical Trials Showed (and Their Limits)

The CLARITY-AD trial was a randomized, placebo-controlled study—the gold standard for testing effectiveness. That strengthens confidence in the findings.

However, there are important limitations:

Follow-up was about 18 months. We do not yet know the long-term durability of benefit.
Participants were carefully selected and generally healthier than some real-world patients.
The trial focused on early Alzheimer’s disease only.

We do not yet know whether continued treatment beyond the trial period maintains, increases, or levels off in benefit. We also do not have evidence that these drugs meaningfully change outcomes in moderate or advanced stages.

6. Real-World Logistics: Infusions, Costs, Caregiver Impact

Lecanemab is given by intravenous infusion every two weeks. That means:

Regular trips to an infusion center
Time for the infusion itself and observation afterward
Scheduled MRI scans
Neurology visits for monitoring

For many families, the caregiver time commitment is significant. Transportation, missed work, and coordination of imaging and appointments can add strain.

Access may also depend on whether local clinics have the staffing and imaging capacity to provide both infusions and timely MRI monitoring.

Before starting therapy, families should discuss:

Total expected visit frequency
Transportation needs
Insurance coverage details
Whether the patient’s overall health supports regular infusions

7. Key Questions to Ask Your Doctor

Is this definitely early Alzheimer’s disease, and how was it diagnosed?
Has amyloid been confirmed with PET or spinal fluid testing?
What did the MRI show? Are there existing microbleeds?
Should we test for APOE ε4 status?
What is the realistic goal for this patient over the next 1–2 years?
What will out-of-pocket costs likely be under our Medicare plan?

8. What Researchers Still Don’t Know

Even with FDA approval and Medicare coverage, several questions remain:

How long should treatment continue?
Does benefit persist beyond the trial period?
Will earlier detection (including emerging blood tests) change who qualifies in the future?
What are the long-term safety outcomes in broader, more medically complex populations?

Ongoing registry data required by CMS may help answer some of these questions over time.

What This Means for Readers

Anti-amyloid antibody drugs are now part of Alzheimer’s care in the United States—but they are not for everyone.

They are intended for people with early symptomatic Alzheimer’s disease and confirmed amyloid buildup. Medicare generally covers them under specific conditions, including required data collection and MRI safety monitoring.

The benefit is best understood as slowing decline, not restoring memory or curing dementia. Treatment involves regular infusions, MRI scans, and careful monitoring for brain swelling or bleeding.

For some families, that tradeoff may be worthwhile. For others, the logistical burden, risks, or costs may outweigh the expected benefit. An informed conversation with a neurologist—grounded in stage of disease, imaging results, and personal goals—is the most important next step.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.